4-(2-噻吩基)苄胺 | 203436-48-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-噻吩基)苄胺
• 英文名称: 4-(2-thienyl)benzylamine
• 英文别名: 1-(4-thiophen-2-ylphenyl)methanamine；(4-thiophen-2-ylphenyl)methanamine
• CAS: 203436-48-0
• 化学式: C₁₁H₁₁NS
• 分子量: 189.281
• InChiKey: YKNLMMDEWQZCLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  322.5±30.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  54.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2934999090

SDS

Name:	4-(2-Thienyl)benzylamine 95+% Material Safety Data Sheet
Synonym:
CAS:	203436-48-0

Section 1 - Chemical Product MSDS Name:4-(2-Thienyl)benzylamine 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
203436-48-0	4-(2-Thienyl)benzylamine	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 203436-48-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11NS
Molecular Weight: 189.28

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 203436-48-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(2-Thienyl)benzylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 3259
Packing Group: III
IMO
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing Group: III
RID/ADR
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 203436-48-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 203436-48-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 203436-48-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-噻吩基)苄胺 在 三氟乙酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.08h， 生成 1-(2S-2-aminobutanoyl)-4-(p-[thiophen-2-yl]benzyl)semicarbazide
  参考文献：
  名称：

  Novel semicarbazide-derived inhibitors of human dipeptidyl peptidase I (hDPPI)

  摘要：

  Human dipeptidyl peptidase 1 (hDPPI, cathepsin C, EC 3.4.14.1) is a novel putative drug target for the treatment of inflammatory diseases. Using 1 as a starting point (IC50 > 10 mu M), we have improved potency by more than 500-fold and successfully identified novel inhibitors of DPPI via screening of a one-bead-two-compounds library of semicarbazide derivatives. Selected compounds were shown to inhibit intracellular DPPI in RBL-2H3 cells. These compounds were further characterized for adverse effects on HepG2 cells (cytotoxicity and viability) and their metabolic stability in rat liver microsomes was estimated. One of the most potent inhibitors, 8 (IC50 = 31 +/- 3 nM; K-i = 45 +/- 2 nM, competitive inhibition), is selective for DPPI over other cysteine and serine proteases, has a half-life of 24 min in rat liver microsomes, shows approximately 50% inhibition of intracellular DPPI at 20 mu M and is noncytotoxic. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.04.048
• 作为产物：
  描述：

  2-氯-7H-吡咯并[2,3-d]嘧啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 14.0h， 生成 4-(2-噻吩基)苄胺
  参考文献：
  名称：

  基于结构的新型 G 蛋白偶联受体 TAAR1 激动剂作为潜在抗精神病药物候选物的设计

  摘要：

  现有的抗精神病药物未能治疗精神分裂症的认知障碍，并引发了许多严重的不良反应。痕量胺相关受体 1 (TAAR1) 已成为抗精神分裂症药物设计的理想靶标，能够通过感知内源性含胺代谢物来介导多种心理功能，而不会产生僵住症的副作用。在这项工作中，基于TAAR1激活口袋的结构分析，设计了一系列新型TAAR1激动剂。其中， 6e表现出有效的TAAR1-G s /G q双通路激活特性，与仅激活TAAR1-G s通路的临床候选药物SEP-363856不同。在啮齿动物模型中， 6e显着减轻 MK-801 诱导的精神分裂症样认知表型，但不会诱发僵直症。此外， 6e·HCl表现出良好的药代动力学（ T 1/2 = 2.31 h， F = 39%）和安全特性。这些都表明6e·HCl可作为治疗精神分裂症的新候选药物。

  DOI：

  10.1021/acs.jmedchem.4c00195

文献信息

• Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors
  作者：Han Ju、Jian Zhang、Zhuosen Sun、Zheng Huang、Wenbao Qi、Bing Huang、Peng Zhan、Xinyong Liu

  DOI：10.1016/j.ejmech.2018.01.050

  日期：2018.2

  Inspired by our initial discovery about a series of neuraminidase (NA) inhibitors targeting the 150-cavity, in present study, we designed, synthesized, and biologically tested a panel of novel oseltamivir derivatives with C-1 modification, targeting the 430-cavity, an additional binding site which widely and stably existed in both group-1 and group-2 NAs. Some of the synthesized compounds displayed

  受我们最初发现一系列针对150腔的神经氨酸酶（NA）抑制剂的启发，在本研究中，我们设计，合成并生物测试了一系列具有C-1修饰作用的新型奥司他韦衍生物，针对430腔，在第1组和第2组NA中广泛稳定地存在的另一个结合位点。一些合成的化合物对H5N1和H5N6病毒显示出强大的抗流感效力。其中，化合物8b对H5N1和H5N6菌株的抑制作用最大，IC50值为0.088和0.097μM，EC50值为4.26和1.31μM，与奥司他韦羧酸盐（OSC）相似。而且它对突变H5N1-H274Y NA的效力比OSC弱7倍。分子模型揭示了在C-1位置的细长基团被投射向430腔。值得注意的是，尽管在胚胎蛋模型中化合物8b对H5N1菌株相对于OSC不敏感，但在浓度为10 mmol / L的情况下，它对H5N6菌株的抗流感病毒作用比对OSC更大。总体而言，这项工作为发现针对第1组和第2组NA的有效抑制剂提供了独特的见解。
• SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
  申请人：Herdewijn Piet André Maurits Maria

  公开号：US20090318456A1

  公开（公告）日：2009-12-24

  Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections.

  三取代喹啉和四取代喹啉对某些类型的病毒感染表现出显著和选择性的活性，特别是它们选择性地抑制丙型肝炎病毒的复制，并可用于预防和治疗此类感染。
• SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS
  申请人：Herdewijn Piet Andre' Maurits Maria

  公开号：US20090253696A1

  公开（公告）日：2009-10-08

  This invention provides di-, tri- and tetra-substituted pyrido(3,2-d)pyrimidine derivatives with specific substituting patterns, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular being highly active antiviral agents. The invention also provides use of such derivatives in the treatment of viral infections and pathologic conditions associated therewith, including hepatitis C.

  这项发明提供了具有特定取代模式的二、三和四取代吡啶并[3,2-d]嘧啶衍生物，其药学上可接受的盐、N-氧化物、溶剂合物、前药和对映体，具有意外地理想的药理特性，特别是作为高活性抗病毒剂。该发明还提供了利用这些衍生物治疗病毒感染及相关病理状况，包括丙型肝炎的用途。
• Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2)
  作者：Nihar Kinarivala、Ronak Patel、Rose-Mary Boustany、Abraham Al-Ahmad、Paul C. Trippier

  DOI：10.1021/acs.jmedchem.7b01199

  日期：2017.12.14

  etoposide-induced apoptosis at concentrations as low as 100 nM. The developed aromatic carbamates possess physicochemical properties desirable for CNS therapeutics. The primary known mechanisms of action of the parent scaffold are not responsible for the observed neuroprotective activity. Herein, we demonstrate that neuroprotective aromatic carbamates function to increase the Bcl-2/Bax ratio to an antiapoptotic state

  神经退行性疾病具有某些病理生理学特征，这些特征代表了药物发现的共同目标。特别是，蛋白稳态失调和由此导致的神经元凋亡死亡代表了药理干预的常见途径。合成了基于临床可用药物氟吡汀的芳香族氨基甲酸酯衍生物库，以确定神经保护活性的结构-活性关系。鉴定出几种衍生物，它们在人诱导的多能干细胞衍生的神经元中具有更大的保护作用，可在低至100 nM的浓度下保护高达80％的神经元免受依托泊苷诱导的凋亡。所开发的芳族氨基甲酸酯具有中枢神经系统治疗剂所需的理化性质。亲本支架的主要已知作用机制与观察到的神经保护活性无关。在本文中，我们证明了神经保护性芳香族氨基甲酸酯的功能是将Bcl-2 / Bax比值提高至抗凋亡状态，并通过诱导Beclin 1激活自噬。
• [EN] 5-SUBSTITUTED-7-[4-(SUBSTITUTED)BENZYL]AMINO-3-ISOPROPYLPYRAZOLO(4,3-D)PYRIMIDINES AS MEDICAMENTS<br/>[FR] UTILISATION DE PYRIMIDINES 5-SUBSTITUÉES-7-[4-(SUBSTITUÉE)BENZYL]AMINO-3-ISOPROPYLPYRAZOLO(4,3-D) EN TANT QUE MÉDICAMENTS
  申请人：USTAV EXPERIMENTALNI BOTANIKY AV CR V V I

  公开号：WO2017012599A1

  公开（公告）日：2017-01-26

  The present invention relates to 5-substituted-7-[4-(substituted)benzyl]amino-3- isopropylpyrazolo[4,3-d]pyrimidines of formula (I) which are effective inhibitors od cyclin- dependent kinases and exhibit strong anti-inflammatory properties. This invention further relates to processes for their preparation, to pharmaceutical compositions comprising said compounds and to their use for the treatment of antiiflammatory disorders such as rheumatoid arthritis.

  本发明涉及式(I)的5-取代-7-[4-(取代)苄基]氨基-3-异丙基吡唑并[4,3-d]嘧啶，它们是有效的细胞周期依赖性激酶抑制剂，并具有强大的抗炎性能。本发明还涉及它们的制备方法，包括所述化合物的药物组合物，以及它们用于治疗风湿性关节炎等抗炎性疾病的用途。